Stock comparison
Haemonetics
NeuroPace
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
NPCE
NeuroPace
Market cap
$576.87M
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | NPCE | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 32F | HAE |
| Benjamin Graham | 85A | 75D | HAE |
| Philip Fisher | 60C | 51C | HAE |
| Peter Lynch | 54C | 68C | NPCE |
| Joel Greenblatt | 31F | 2F | HAE |
| Charlie Munger | 54D | 35D | HAE |
| Terry Smith | 55D | 30F | HAE |
Side-by-side metrics
| Metric | HAE | NPCE |
|---|---|---|
| Market cap | $2.98B | $576.87M |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -19.74% |
| Gross margin | 55.74% | 78.29% |
| Net margin | 7.29% | -14.95% |
| Revenue CAGR 5y | 7.65% | 21.97% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 4.9x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -14.95%+149%
- ROIC (TTM)8.37%vs -19.74%+142%
- Market cap$2.98Bvs $576.87M+81%
- Debt / Equity1.5xvs 4.9x+68%
NPCE leads on
- P/E (TTM)-vs 24.8x+169%
- EV/EBIT-vs 14.1x+139%
- Revenue CAGR 5y21.97%vs 7.65%+65%
- Gross margin78.29%vs 55.74%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.